Regulation of G protein-coupled receptor-adenylyl cyclase responsiveness in human airway smooth muscle by exogenous and autocrine adenosine.
Adenosine is a mediator of bronchoconstriction in asthmatics and is believed to mediate its effects through adenosine receptor activation in inflammatory cells. In this study, we identify human airway smooth muscle (ASM) as a direct target of adenosine. Acute exposure of human ASM cultures to adenosine receptor (AR) agonists resulted in rapid accumulation of cyclic adenosine monophosphate (cAMP) with a pharmacologic profile consistent with A(2b)AR activation. Little or no evidence of A1AR or A3AR expression was suggested on acute addition of various AR ligands, although a low level of A1ARs was identified in radioligand binding studies. Treatment with adenosine deaminase suggested that human ASM cultures secrete adenosine that feeds back on A(2b)ARs and regulates basal cAMP levels as well as a small degree of A(2b)AR, beta(2)AR, and prostaglandin E(2) receptor desensitization. When subjected to chronic treatment with AR agonists or agents that enhance accumulation of endogenous, extracellular adenosine, a dual effect of A(2b)AR desensitization and adenylyl cyclase (AC) sensitization was observed. This AC sensitization was eliminated by pertussis toxin and partially reversed by the A1AR antagonist 8-cyclopentyl-1,3-dipropylxanthine, suggesting a contributory role for the A1AR. Overexpression of A1ARs and A(2b)ARs in human ASM cultures resulted in differential effects on basal, agonist-, and AC-mediated cAMP production. These data demonstrate that human ASM is a direct target of exogenous and autocrine adenosine, with effects determined by differential contributions of A(2b) and A1 adenosine receptors that are time-dependent. Accordingly, the relative distribution and activation of AR subtypes in ASM in vivo may influence airway function in diseases such as asthma and warrant consideration in therapeutic strategies that target ARs or alter nucleotide/ nucleoside levels in the airway.
Mundell
S J
SJ
Department of Microbiology and Immunology, Kimmel Cancer Institute, Thomas Jefferson University, 233 S. 10th St., Philadelphia, PA 19107, USA.
Olah
M E
ME
Panettieri
R A
RA
Benovic
J L
JL
Penn
R B
RB
D000241:Adenosine / Q000378:metabolism / Q000494:pharmacology*; D019830:Adenosine-5'-(N-ethylcarboxamide) / Q000494:pharmacology; D000262:Adenylyl Cyclases / Q000187:drug effects* / Q000378:metabolism*; D002478:Cells, Cultured / Q000187:drug effects; D000242:Cyclic AMP / Q000096:biosynthesis; D017931:DNA Primers / Q000737:chemistry; D005453:Fluorescence; D020555:GTP-Binding Protein Regulators / Q000494:pharmacology*; D015971:Gene Expression Regulation, Enzymologic; D049452:Green Fluorescent Proteins; D006801:Humans; D007527:Isoenzymes / Q000096:biosynthesis / Q000378:metabolism; D008164:Luminescent Proteins / Q000378:metabolism; D009130:Muscle, Smooth / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology; D016133:Polymerase Chain Reaction; D058915:Purinergic P1 Receptor Antagonists; D012333:RNA, Messenger / Q000032:analysis; D043704:Receptor, Adenosine A2B; D012137:Respiratory System / Q000166:cytology / Q000187:drug effects* / Q000201:enzymology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014162:Transfection
D017931:DNA Primers; D020555:GTP-Binding Protein Regulators; D007527:Isoenzymes; D008164:Luminescent Proteins; D058915:Purinergic P1 Receptor Antagonists; D012333:RNA, Messenger; D043704:Receptor, Adenosine A2B; D049452:Green Fluorescent Proteins; D019830:Adenosine-5'-(N-ethylcarboxamide); D000242:Cyclic AMP; D000262:Adenylyl Cyclases; D000241:Adenosine